Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer.
A review of 78 previously untreated patients with bidimensionally measurable metastatic bladder cancer who were entered into a series of studies of cytotoxic chemotherapy has shown that complete response occurred in 1 of 23 patients receiving methotrexate, none of 15 receiving cisplatin, none of 20 receiving the platinum analogue carboplatin and 3 (2 with histological confirmation) of 20 receiving methotrexate in combination with cisplatin. WHO/UICC performance status 3 and 4, though a prediction of lower response, did not provide a means for excluding patients who might benefit from chemotherapy. Studies using serial cytology showed that 5 of 8 responders according to standard criteria had complete loss of malignant cells from the urine compared with none of 10 non-responders and there was a suggestion that duration of response was longer in those whose urine was negative for malignant cells than in those which remained positive.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary / Q000652:urine; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014556:Urine / Q000166:cytology; D014571:Urologic Neoplasms / Q000188:drug therapy / Q000652:urine
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin; D002945:Cisplatin; D008727:Methotrexate